Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial
- PMID: 26314489
- DOI: 10.1016/S0140-6736(15)61485-4
Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): a randomised controlled trial
Abstract
Background: The Valsalva manoeuvre is an internationally recommended treatment for supraventricular tachycardia, but cardioversion is rare in practice (5-20%), necessitating the use of other treatments including adenosine, which patients often find unpleasant. We assessed whether a postural modification to the Valsalva manoeuvre could improve its effectiveness.
Methods: We did a randomised controlled, parallel-group trial at emergency departments in England. We randomly allocated adults presenting with supraventricular tachycardia (excluding atrial fibrillation and flutter) in a 1:1 ratio to undergo a modified Valsalva manoeuvre (done semi-recumbent with supine repositioning and passive leg raise immediately after the Valsalva strain), or a standard semi-recumbent Valsalva manoeuvre. A 40 mm Hg pressure, 15 s standardised strain was used in both groups. Randomisation, stratified by centre, was done centrally and independently, with allocation with serially numbered, opaque, sealed, tamper-evident envelopes. Patients and treating clinicians were not masked to allocation. The primary outcome was return to sinus rhythm at 1 min after intervention, determined by the treating clinician and electrocardiogram and confirmed by an investigator masked to treatment allocation. This study is registered with Current Controlled Trials (ISRCTN67937027).
Findings: We enrolled 433 participants between Jan 11, 2013, and Dec 29, 2014. Excluding second attendance by five participants, 214 participants in each group were included in the intention-to-treat analysis. 37 (17%) of 214 participants assigned to standard Valsalva manoeuvre achieved sinus rhythm compared with 93 (43%) of 214 in the modified Valsalva manoeuvre group (adjusted odds ratio 3·7 (95% CI 2·3-5·8; p<0·0001). We recorded no serious adverse events.
Interpretation: In patients with supraventricular tachycardia, a modified Valsalva manoeuvre with leg elevation and supine positioning at the end of the strain should be considered as a routine first treatment, and can be taught to patients.
Funding: National Institute for Health Research.
Copyright © 2015 Appelboam et al. Open Access article distributed under the terms of CC BY-ND-NC. Published by Elsevier Ltd.. All rights reserved.
Comment in
-
Supraventricular tachycardia: back to basics.Lancet. 2015 Oct 31;386(10005):1712. doi: 10.1016/S0140-6736(15)61514-8. Epub 2015 Aug 24. Lancet. 2015. PMID: 26314491 No abstract available.
-
[Modified Valsalva maneuver in patients with supraventricular tachycardia].Praxis (Bern 1994). 2015 Nov 25;104(24):1349-50. doi: 10.1024/1661-8157/a002210. Praxis (Bern 1994). 2015. PMID: 26602854 German. No abstract available.
-
A modified Valsalva maneuver was more effective than standard Valsalva for treating supraventricular tachycardia.Ann Intern Med. 2015 Dec 15;163(12):JC8. doi: 10.7326/ACPJC-2015-163-12-008. Ann Intern Med. 2015. PMID: 26666810 No abstract available.
-
A modified Valsalva manoeuvre results in greater termination of supraventricular tachycardia than standard Valsalva manoeuvre.Evid Based Med. 2016 Apr;21(2):61. doi: 10.1136/ebmed-2015-110357. Epub 2016 Jan 4. Evid Based Med. 2016. PMID: 26729773 No abstract available.
-
A modification to the Valsalva manoeuvre improves its effectiveness in treating supraventricular tachycardia.Evid Based Nurs. 2016 Jul;19(3):77. doi: 10.1136/ebnurs-2016-102329. Epub 2016 Apr 15. Evid Based Nurs. 2016. PMID: 27083492 No abstract available.
-
Leg Lift Valsalva Maneuver for Treatment of Supraventricular Tachycardias.CJEM. 2017 May;19(3):235-237. doi: 10.1017/cem.2016.341. Epub 2016 Aug 12. CJEM. 2017. PMID: 27514458
-
Modified Valsalva and much more: lessons learned from the REVERT trial.Eur J Emerg Med. 2016 Dec;23(6):458-459. doi: 10.1097/MEJ.0000000000000373. Eur J Emerg Med. 2016. PMID: 27755148 No abstract available.
-
Lessons from the REVERT trial.Eur J Emerg Med. 2016 Dec;23(6):459-460. doi: 10.1097/MEJ.0000000000000396. Eur J Emerg Med. 2016. PMID: 27755149 No abstract available.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials
